Zobrazeno 1 - 10
of 460
pro vyhledávání: '"Michael J. Kelley"'
Autor:
Katherine I. Zhou, MD, PhD, Chenyu Lin, MD, Chin-Lin Tseng, MPH, Nithya Ramnath, MBBS, Jonathan E. Dowell, MD, Michael J. Kelley, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 5, Pp 100670- (2024)
Introduction: The KRAS G12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, data on the real-world efficacy and safety of sotorasib, and to its optimal dos
Externí odkaz:
https://doaj.org/article/4f1e08331e2f48cd94d301fa4fe9842e
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3520-3531 (2023)
Abstract Background Cancer diagnoses are associated with an increased risk for suicide. The aim of this study was to evaluate this association among Veterans receiving Veterans Health Administration (VHA) care, a population that has an especially hig
Externí odkaz:
https://doaj.org/article/3bcef7a272fa4c87878f9706b546c52d
Publikováno v:
Physical Review Accelerators and Beams, Vol 26, Iss 10, p 103101 (2023)
Surface finish plays an essential role in the performance of superconducting radio frequency cavities. Several surface treatments have been developed to reduce surface resistance at a moderate accelerating gradient. We investigated the effects of seq
Externí odkaz:
https://doaj.org/article/e15e8288f904472fa9e8433f3fa62015
Autor:
Anna Hung, Kyung Min Lee, Julie A. Lynch, Yanhong Li, Pradeep Poonnen, Olga V. Efimova, Bradley J. Hintze, Trudy Buckingham, Candice Yong, Brian Seal, Michael J. Kelley, Shelby D. Reed
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background The Veterans Health Administration (VHA) is the largest integrated health care system in the United States (US). Among VHA patients, the rate of use of concurrent chemoradiation therapy (CCRT) among those with unresectable, stage
Externí odkaz:
https://doaj.org/article/750fdfa47ed44f2a96ca37f437898721
Autor:
Shelley A. Jazowski, Isabelle P. Sico, Jennifer H. Lindquist, Valerie A. Smith, Hayden B. Bosworth, Susanne Danus, Dawn Provenzale, Michael J. Kelley, Leah L. Zullig
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Transportation barriers limit access to cancer care services and contribute to suboptimal clinical outcomes. Our objectives were to describe the frequency of Veterans reporting and the factors associated with transportation barrie
Externí odkaz:
https://doaj.org/article/5d1eb0ded13746f78af0309b30e7d872
Autor:
A. Jasmine Bullard, Francesca E. Cunningham, Bryan D. Volpp, Elliott Lowy, Lauren A. Beste, Bernadette B. Heron, Mark Geraci, Julia M. Hammond, Kourtney LaPlant, Elise A. Stave, Marsha J. Turner, Meghan C. O’Leary, Michael J. Kelley, Christine M. Hunt
Publikováno v:
Hepatology Communications, Vol 2, Iss 9, Pp 1136-1146 (2018)
Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti‐cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti‐CD20 Ab therapy averts hepatitis, chemotherapy disruption, a
Externí odkaz:
https://doaj.org/article/f5f8e6b9ad18483d989c186a77b81343
Autor:
Anna Hung, Kyung Min Lee, Patrick R. Alba, Yanhong Li, Anthony Z. Gao, Bradley J. Hintze, Olga V. Efimova, Rahul Shenolikar, Melissa Pavilack, Dan Simmons, Michael J. Kelley, Julie A. Lynch, Shelby D. Reed
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100327- (2021)
Background: Epidermal growth factor receptor (EGFR) mutation testing is recommended in metastatic non-small cell lung cancer (NSCLC). The objective of this study was to assess changes in EGFR mutation testing patterns and tyrosine kinase inhibitor (T
Externí odkaz:
https://doaj.org/article/9e110d6a593c49f49e384d7fd0b54e43
Autor:
Kamya Sankar, Alex K. Bryant, Garth W. Strohbehn, Lili Zhao, David Elliott, Drew Moghanaki, Michael J. Kelley, Nithya Ramnath, Michael D. Green
Publikováno v:
Cancers, Vol 14, Iss 3, p 614 (2022)
One year of durvalumab following concurrent chemoradiotherapy improves progression-free (PFS) and overall survival (OS) for patients with stage III non-small cell lung cancer (NSCLC). However, the real-world efficacy of durvalumab has not been determ
Externí odkaz:
https://doaj.org/article/74d2fe1720e14fbfa555b262217dec80
Autor:
Leah L. Zullig, Karen M. Goldstein, Hayden B. Bosworth, Sara M. Andrews, Susanne Danus, George L. Jackson, Dawn Provenzale, Morris Weinberger, Michael J. Kelley, Corrine I. Voils
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the US. CRC survivors may have complex healthcare needs requiring care from both specialists and primary care. Our objective was to understand how CRC survivor
Externí odkaz:
https://doaj.org/article/f238e93e7fb1440ca29aa0dcf3a9b660
Autor:
Olga Efimova, Brygida Berse, Daniel W. Denhalter, Scott L. DuVall, Kelly K. Filipski, Michael Icardi, Michael J. Kelley, Julie A. Lynch
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background Current clinical guidelines recommend epidermal growth factor receptor (EGFR) mutational testing in patients with metastatic non-small cell lung cancer (NSCLC) to predict the benefit of the tyrosine kinase inhibitor erlotinib as f
Externí odkaz:
https://doaj.org/article/3d478c1b7eaf418391bcb859a5898ca9